A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models

AIDS

Volumn 26, Issue 2, 2012, Pages 127-137

  Berzi, Angela ^a   Reina, José J ^b   Ottria, Roberta ^b   Sutkeviciute, Ieva ^d,e,f   Antonazzo, Patrizio ^a   Sanchez Navarro, MacArena ^h   Chabrol, Eric ^d,e,f   Biasin, Mara ^a   Trabattoni, Daria ^a   Cetin, Irene ^a   Rojo, Javier ^h   Fieschi, Franck ^d,e,f,g   Bernardi, Anna ^b,i   Clerici, Mario ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d UNIV GRENOBLE ALPES   (France)

^e DIF   (France)

^f CNRS   (France)

^g INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^h CSIC   (Spain)

ⁱ CNR   (Italy)

Author keywords

cervical explants; DC SIGN; glycomimetic drugs; HIV; topical microbicides

Indexed keywords

BETA CHEMOKINE; CD209 ANTIGEN; GLYCOSIDE; LANGERIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; EXPLANT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; UTERINE CERVIX; VIRUS LOAD;

ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CERVIX UTERI; CHEMOKINES, CC; DENDRIMERS; DENDRITIC CELLS; FEMALE; GLYCOSYLATION; HIV INFECTIONS; HIV-1; HUMANS; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; RECEPTORS, CELL SURFACE; RECEPTORS, HIV;

EID: 84155170821     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e1567     Document Type: Article

References (48)

1. UNAIDS Report on the global AIDS epidemic, 2010.
2. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV infection. Lancet Infect Dis 2008; 8:685-697.
3. Reina JJ, Bernardi A, Clerici M, Rojo J. HIV microbicides: stateof-the-art and new perspectives on the development of entry inhibitors. Future Med Chem 2010; 2:1141-1159.
4. Geijtenbeek TBH, Torensma R, van Vliet SJ, van Duijnhoven GCF, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100:575-585.
5. Pope M, Haase AT. Transmission, cute HIV infection and the quest for strategies to prevent infection. Nat Med 2003; 9:847-852.
6. Wu L, Wu L, KevalRamani VL. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol 2006; 6:859-868.
7. Geijtenbeek TBH, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GCF, Middel J, et al. DC-SIGN, a dendritic cellspecific HIV-1-binding protein that enhances trans-infection of T Cells. Cell 2000; 100:587-597.
8. Van Kooyk Y, Geijtenbeeck TBH. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003; 3:697-709.
9. Kwon DS, Gregorio G, Bitton N, Hendrikson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002; 16:135-144.
10. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003; 300:1295-1297.
11. Wiley RD, Gummuluru S. Immature dendritic cells derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci USA 2006; 103:738-743.
12. Lee B, Leslie G, Soilleux E, O'Doherty U, Baik S, Levroney E, et al. Cis expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a co-receptor. J Virol 2001; 75:12028-12038.
13. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2003; 103:2170-2179.
14. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek TBH. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kB. Immunity 2007; 26: 605-616.
15. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007; 8:569-577.
16. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TBH. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010; 11:419-426.
17. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TBH. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2010; 10:1081-1089.
18. Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001; 294:2163-2166.
19. Adams EW, Ratner DM, Bokesch HR, McMahon JB, O'Keefe BR, Seeberger PH. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycandependent gp120/protein interactions. Chem Biol 2004; 11:875-881.
20. Reina JJ, Sattin S, Invernizzi D, Mari S, Martínez-Prats L, Tabarani G, et al. 1,2 Mannobioside mimic: synthesis, DCSIGN interaction by NMR and docking, and antiviral activity. Chem MedChem 2007; 2:1030-1036.
21. Rojo J, Delgado R. Glycodendritic structures: promising new antiviral drugs. J Antimicrob Chemother 2004; 54:579-581.
22. Luczkowiak J, Sattin S, Sutkevičiute I, Reina JJ, Sánchez-Navarro M, Thépaut M, et al. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection. Bioconj Chem 2011; 22:1354-1365.
23. Sattin S, Daghetti A, Thépaut M, Berzi A, Sanchez-Navarro M, Rojo J, et al. Inhibition of DC-SIGN-mediated infecion by a linear trimannoside mimic in a tetravalent presentation. ACS Chem Biol 2010; 5:301-312.
24. Anderson DJ, Pudney J, Shust DJ. Caveat associated with the use of human cervical tissue for HIV and microbicide research. AIDS 2010; 24:1-4.
25. Greenhead P, Hayes P, Watts P, Laing K, Griffin G, Shattock R. Parameters of Human Immunodeficiency Virus Infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-5586.
26. Wallace GS, Cheng-Mayer C, Schito ML, Fletcher P, Miller Jenkins LM, Hayashi R, et al. Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol 2009; 83:9175-9182.
27. Cummins JE, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, et al. Preclinical testing of candidate topical microbicides for antihuman immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007; 51:1770-1779.
28. Thépaut M, Valladeau J, Nurisso A, Kahn R, Arnou B, Vivès C, et al. Structural studies of Langerin and Birbeck granule: a macromolecular organization model. Biochemistry 2009; 48:2684-2698.
29. Tabarani G, Thépaut M, Stroebel D, Ebel C, Vivès C, Vachette P, et al. DC-SIGN neck domain is a pH-sensor controlling oligomerization: SAXS and hydrodynamic studies of extracellular domain. J Biol Chem 2009; 284:21229-21240.
30. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houlès C, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell transinfection. Immunity 2002; 17:653-664.
31. Andreini M, Doknic D, Sutkeviciute I, Reina JJ, Duan J, Chabrol E, et al. Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. Org Biomol Chem 2011; 9:5778-5786.
32. Wu L, Martin TD, Carrington M, KewalRamani VN. Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. Virology 2004; 318:17-23.
33. de Witte L, Nabatov A, Pion M, Fluitsma D, Marein AW, de Jong P, et al. Langerin is natural barrier to HIV-1 transmission by langerhans cells. Nat Med 2007; 13:367-371.
34. de Witte L, Nabatov A, Geijtenbeek TBH. Distinct roles for DC-SING-dentritic cells and langherans cells in HIV-1 transmission. Trends Mol Med 2007; 14:12-19.
35. Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol 2004; 11:591-598.
36. Galustian C, Park CG, Chai W, Kiso M, Bruening SA, Kang YS, et al. High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and Langerin. Int Immunol 2004; 16:853-866.
37. Timpano G, Tabarani G, Anderluh M, Invernizzi D, Vasile F, Potenza D, et al. Synthesis of novel DC-SIGN ligands with an alpha-fucosylamide anchor. ChemBioChem 2008; 9:1921-1930.
38. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-1118.
39. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
40. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 2008; 105:3690-3695.
41. Martinez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcami J, Penades S. Multivalent manno-glyconanoparticles inhibit DCSIGN-mediated HIV-1 trans-infection of human T cells. Chem Biochem 2009; 10:1806-1809.
42. Nazari R, Joshi S. CCR5 as target for HIV-1 gene therapy. Curr Gene Ther 2008; 8:1-9.
43. McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS 2000; 14 (Suppl 3):S31-S44.
44. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51:229-240.
45. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 26:722-725.
46. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997; 186:1373-1381.
47. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1(, and MIP-1( as the major HIV-1-suppressive factors produced by CD8 T cells. Science 1995; 270:1811-1815.
48. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969; 20:85-93.